

Impact of HIV on Hemophilia Patients: A Review

*Emmanuel Ifeanyi Obeagu¹ and Sharon Seni Itoe Ngomo²

¹Department of Medical Laboratory Science, Kampala International University, Uganda

²Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon

*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

The coexistence of hemophilia and HIV represents a unique medical challenge, with profound implications for affected individuals and healthcare systems worldwide. This review comprehensively examines the impact of HIV on hemophilia patients, encompassing epidemiological trends, clinical manifestations, therapeutic considerations, and implications for patient care. While advancements in screening and treatment have reduced the risk of HIV transmission through clotting factor concentrates in many high-income countries, challenges persist in resource-limited settings. Moreover, disparities in HIV prevalence among older individuals with hemophilia underscore the enduring legacy of past exposures and the need for ongoing vigilance in surveillance and prevention efforts. Clinically, HIV infection in hemophilia patients is associated with a broad spectrum of complications, ranging from immunological dysfunction to hematological abnormalities and psychosocial challenges. Immunodeficiency resulting from HIV predisposes individuals to opportunistic infections and malignancies, exacerbating existing hemophilia-related complications and complicating clinical management. Furthermore, the psychosocial impact of living with both conditions, including stigma, discrimination, and mental health concerns, underscores the importance of holistic, patient-centered care approaches.

Introduction

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. Elite Journal of HIV, 2024; 2(5): 9-27

The intersection of hemophilia and HIV presents a unique and multifaceted medical challenge, intertwining two complex conditions with distinct pathophysiological mechanisms and clinical manifestations. Hemophilia, a rare genetic bleeding disorder characterized by deficiencies or dysfunction in clotting factors, has historically posed significant clinical and psychosocial burdens for affected individuals and their families. Conversely, HIV, a viral infection that targets the immune system, has had a profound impact on global health since its emergence in the early 1980s, leading to millions of deaths and widespread social and economic repercussions. The convergence of these conditions in certain populations, particularly individuals with hemophilia who received contaminated blood products before the implementation of rigorous screening measures, has further compounded the complexities of disease management and highlighted the interplay between coagulation disorders and infectious diseases. The epidemiology of HIV in hemophilia patients reflects a dynamic interplay of historical, social, and healthcare factors, with distinct temporal trends and geographic variations observed over time. Prior to the implementation of effective screening protocols, individuals with hemophilia were disproportionately affected by HIV due to the widespread use of contaminated clotting factor concentrates derived from pooled plasma donations. While advancements in blood product safety and antiretroviral therapy have reduced the risk of HIV transmission and improved outcomes for affected individuals in many high-income countries, disparities persist, particularly in resource-limited settings where access to care and preventive measures may be limited. Moreover, the enduring legacy of past exposures underscores the importance of ongoing surveillance and prevention efforts to mitigate the long-term impact of HIV on hemophilia patients.¹⁻³⁰

Clinically, the coexistence of hemophilia and HIV presents a myriad of challenges, spanning hematological, immunological, and psychosocial domains. Hemophilia patients with HIV are at increased risk of bleeding complications, opportunistic infections, and thrombotic events, necessitating comprehensive and multidisciplinary approaches to disease management. Immunodeficiency resulting from HIV infection predisposes individuals to recurrent infections and malignancies, further exacerbating existing hemophilia-related complications and complicating clinical decision-making. Additionally, the psychosocial impact of living with both conditions, including stigma, discrimination, and mental health concerns, underscores the importance of holistic, patient-centered care approaches that address the diverse needs and challenges faced by affected individuals and their families. Therapeutically, the management of hemophilia patients with HIV requires careful consideration of the overlapping pathophysiology and treatment considerations of both conditions. Antiretroviral therapy, aimed at controlling HIV replication and preserving immune function, must be balanced with the risk of drug interactions and adverse effects on clotting factor metabolism. Similarly, hemophilia treatment regimens, including clotting factor replacement therapy and prophylactic regimens, must be tailored to individual patient needs and preferences, taking into account factors such as bleeding phenotype, joint health, and comorbidities. Moreover, the integration of psychosocial support services, adherence interventions, and patient education programs is essential for optimizing treatment outcomes and enhancing the quality of life of individuals living with both hemophilia and HIV.³¹⁻⁵⁰

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

Epidemiology of HIV in Hemophilia

The epidemiological landscape of HIV infection among individuals with hemophilia reflects a complex interplay of historical, social, and healthcare factors, with distinct temporal trends and geographic variations observed over time. Historically, individuals with hemophilia were disproportionately affected by HIV due to the widespread use of contaminated clotting factor concentrates derived from pooled plasma donations during the early years of the HIV epidemic. The introduction of heat treatment and viral inactivation techniques in the mid-1980s marked a significant turning point in blood product safety, leading to a substantial decline in the risk of HIV transmission through clotting factor concentrates in many high-income countries. However, despite these advancements, the legacy of past exposures continues to influence the epidemiology of HIV in hemophilia, particularly among older individuals who were exposed to contaminated products before effective screening measures were implemented. The epidemiological trends of HIV in hemophilia have evolved alongside advancements in blood product safety, antiretroviral therapy, and public health interventions. In high-income countries where access to safe clotting factor concentrates and comprehensive HIV care is readily available, the prevalence of HIV among individuals with hemophilia has declined significantly in recent decades. However, persistent disparities exist, with older cohorts of hemophilia patients remaining disproportionately affected by HIV due to historical exposures. In contrast, low- and middle-income countries may face ongoing challenges in ensuring access to safe blood products and HIV testing and treatment services, leading to higher HIV prevalence rates among hemophilia patients in these regions. Furthermore, the epidemiology of HIV in hemophilia underscores the importance of ongoing surveillance and prevention efforts to mitigate the long-term impact of HIV on affected individuals and their communities. Surveillance systems play a crucial role in monitoring trends in HIV prevalence, incidence, and transmission patterns among hemophilia patients, facilitating targeted interventions and resource allocation. Prevention strategies, including universal HIV testing, access to antiretroviral therapy, and adherence to safe injection practices, are essential for reducing the risk of HIV transmission and improving outcomes for individuals with hemophilia. Moreover, efforts to raise awareness, reduce stigma, and advocate for the rights and dignity of individuals living with both hemophilia and HIV are paramount for fostering supportive healthcare environments and promoting equitable access to care.⁵¹⁻⁸⁰

Clinical Manifestations and Complications

The coexistence of hemophilia and HIV presents a broad spectrum of clinical manifestations and complications, spanning hematological, immunological, and psychosocial domains. Hemophilia patients with HIV are at increased risk of both traditional hemophilia-related complications and HIV-specific manifestations, often leading to complex clinical presentations and challenging management scenarios. One of the primary clinical manifestations in hemophilia patients with HIV is an increased propensity for bleeding complications. HIV-related thrombocytopenia, coagulation abnormalities, and endothelial dysfunction can exacerbate the bleeding phenotype in hemophilia patients, leading to more frequent and severe bleeding episodes. Moreover, hemophilia patients with HIV may experience prolonged bleeding times and delayed wound healing, further

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

complicating the management of surgical procedures, trauma, and spontaneous hemorrhages. Immunodeficiency resulting from HIV infection predisposes individuals to recurrent infections and opportunistic illnesses, which can exacerbate existing hemophilia-related complications and complicate clinical decision-making. HIV-related immunosuppression increases the risk of bacterial, viral, and fungal infections, including respiratory tract infections, opportunistic pneumonias, and septicemia. Additionally, HIV-associated immune dysregulation may contribute to the development of autoimmune phenomena, such as immune thrombocytopenic purpura (ITP), further complicating the clinical picture in hemophilia patients. Furthermore, the psychosocial impact of living with both hemophilia and HIV cannot be overstated and encompasses a range of challenges, including stigma, discrimination, and mental health concerns. Individuals with hemophilia and HIV may face social isolation, financial strain, and disruptions to employment and education due to the perceived stigma associated with their conditions. Moreover, the psychological burden of chronic illness, fear of disease progression, and uncertainty about the future can contribute to anxiety, depression, and diminished quality of life in affected individuals and their families.⁸¹⁻¹⁰⁰

Challenges in Management

The management of hemophilia patients with concurrent HIV infection presents a myriad of challenges stemming from the complex interplay between these two conditions, as well as the unique therapeutic considerations and psychosocial complexities inherent to each. These challenges span diagnostic, therapeutic, and supportive care domains and require a multidisciplinary approach to address the diverse needs of affected individuals and optimize treatment outcomes. One of the foremost challenges in managing hemophilia patients with HIV lies in the accurate diagnosis and characterization of coexisting hematological and infectious complications. Distinguishing between bleeding episodes attributable to hemophilia and those secondary to HIV-related coagulation abnormalities or thrombocytopenia can be challenging, necessitating comprehensive clinical assessments, laboratory investigations, and imaging studies to guide appropriate treatment decisions. Moreover, the presence of comorbidities such as liver disease, renal dysfunction, and opportunistic infections further complicates the clinical picture and requires tailored management strategies.¹⁰¹⁻¹²⁰

Therapeutically, balancing the management of hemophilia and HIV poses unique challenges due to potential drug interactions, adverse effects, and therapeutic conflicts between antiretroviral therapy (ART) and clotting factor replacement therapy. Certain antiretroviral agents, particularly protease inhibitors and non-nucleoside reverse transcriptase inhibitors, may interfere with the metabolism and clearance of clotting factors, leading to altered pharmacokinetics and reduced efficacy of hemophilia treatment. Conversely, some clotting factor concentrates may interact with ART, resulting in increased bleeding risk or drug toxicity. Consequently, healthcare providers must carefully weigh the risks and benefits of concurrent treatment regimens and consider alternative therapeutic options to optimize outcomes while minimizing adverse effects. Moreover, ensuring access to comprehensive care, including specialized hemophilia treatment centers and HIV care facilities, can be challenging, particularly in resource-limited settings where healthcare

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

infrastructure and funding may be inadequate. Individuals with hemophilia and HIV require ongoing monitoring, adherence support, and psychosocial interventions to address the diverse physical, emotional, and social aspects of living with chronic illness. However, barriers such as limited access to healthcare services, medication costs, and stigma associated with HIV and hemophilia may impede engagement in care and exacerbate health disparities among affected individuals. Furthermore, the long-term implications of HIV on hemophilia-related outcomes, such as joint health, quality of life, and life expectancy, necessitate ongoing monitoring and multidisciplinary management approaches. Hemophilia patients with HIV are at increased risk of developing complications such as hemarthrosis, chronic pain, and arthropathy, which can significantly impact mobility, functional independence, and overall well-being. Therefore, comprehensive treatment plans should incorporate strategies to optimize joint health, including prophylactic clotting factor replacement therapy, physical therapy, and joint-preserving interventions.¹²¹⁻¹⁴⁰

Advancements in Therapeutic Approaches

The management of hemophilia patients with HIV has been significantly enhanced by advancements in therapeutic approaches, spanning both hemophilia and HIV care domains. These advancements have revolutionized treatment strategies, improved outcomes, and empowered individuals with hemophilia and HIV to live longer, healthier lives. In the realm of hemophilia treatment, the development and widespread adoption of extended half-life clotting factor concentrates have transformed the landscape of prophylactic and on-demand therapy. Extended half-life products offer prolonged circulation times and less frequent dosing intervals, reducing the burden of treatment and improving adherence among individuals with hemophilia and HIV. Moreover, advancements in gene therapy hold promise for achieving sustained correction of clotting factor deficiencies, potentially offering a curative approach for hemophilia patients with HIV by eliminating the need for lifelong clotting factor replacement therapy.¹⁴¹⁻¹⁵⁰

In the context of HIV care, the advent of combination antiretroviral therapy (cART) has revolutionized the management of HIV infection, transforming it into a chronic, manageable condition. cART regimens, consisting of multiple antiretroviral agents targeting different stages of the HIV lifecycle, suppress viral replication, preserve immune function, and reduce the risk of disease progression and transmission. Moreover, the introduction of novel antiretroviral agents, such as integrase inhibitors and pharmacokinetic enhancers, has expanded treatment options and improved tolerability, efficacy, and adherence compared to earlier generations of drugs. Furthermore, advancements in supportive care and psychosocial interventions have played a pivotal role in enhancing the holistic care of individuals with hemophilia and HIV. Patient-centered care models, incorporating shared decision-making, self-management strategies, and peer support networks, empower individuals to actively participate in their care and advocate for their needs. Moreover, psychosocial support services, including counseling, education, and vocational rehabilitation, address the emotional, social, and practical challenges associated with living with chronic illness and promote resilience and well-being among affected individuals and their families. Additionally, advancements in diagnostic technologies, such as point-of-care testing and

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

novel biomarkers, enable early detection of hemophilia-related complications and HIV-associated comorbidities, facilitating timely intervention and preventive measures. Moreover, advancements in telemedicine and digital health technologies enhance access to care, facilitate remote monitoring, and promote adherence to treatment regimens, particularly for individuals residing in remote or underserved areas.¹⁵¹⁻¹⁶⁰

Implications for Patient Care

The complex interplay between hemophilia and HIV presents profound implications for patient care, necessitating comprehensive, multidisciplinary approaches that address the diverse needs and challenges of affected individuals. One of the primary implications for patient care is the importance of integrated, multidisciplinary care models that provide holistic support for individuals with hemophilia and HIV. Collaborative care teams, consisting of hematologists, infectious disease specialists, nurses, social workers, psychologists, and other healthcare professionals, work together to address the diverse physical, emotional, and social aspects of living with chronic illness. By coordinating care across specialties and incorporating patient-centered approaches, healthcare providers can optimize treatment outcomes, improve adherence to treatment regimens, and enhance the overall quality of life of affected individuals. Furthermore, patient education and empowerment play a pivotal role in enhancing patient care and self-management skills among individuals with hemophilia and HIV. Providing comprehensive information about their conditions, treatment options, and self-care strategies empowers individuals to actively participate in their care, make informed decisions, and advocate for their needs. Moreover, peer support networks and community-based organizations offer valuable opportunities for individuals to connect with others facing similar challenges, share experiences, and access additional resources and support.¹⁶¹⁻¹⁶⁵

Additionally, addressing the psychosocial aspects of living with hemophilia and HIV is paramount for promoting holistic patient care and well-being. Stigma, discrimination, and mental health concerns are pervasive issues faced by individuals with hemophilia and HIV, often exacerbating existing challenges and impacting treatment outcomes. Therefore, integrating psychosocial support services, including counseling, support groups, and peer mentoring programs, into routine care is essential for addressing the emotional, social, and practical needs of affected individuals and their families. Moreover, efforts to promote health equity and reduce disparities in access to care are essential for ensuring that all individuals with hemophilia and HIV receive the comprehensive care they need to thrive. This includes addressing barriers to care, such as financial constraints, transportation issues, and limited access to specialized healthcare services, particularly in underserved and marginalized populations. By advocating for inclusive and equitable healthcare policies and practices, healthcare providers and policymakers can help improve access to care and reduce health disparities among affected individuals.¹⁵¹⁻¹⁶⁰

Conclusion

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. Elite Journal of HIV, 2024; 2(5): 9-27

The convergence of hemophilia and HIV represents a complex and multifaceted intersection of two chronic conditions, characterized by overlapping clinical manifestations, therapeutic considerations, and psychosocial challenges. Despite the significant progress made in understanding and managing these conditions, individuals living with both hemophilia and HIV continue to face unique and often daunting challenges that impact their health, well-being, and quality of life. Integrated care models that bring together hematologists, infectious disease specialists, nurses, social workers, psychologists, and other healthcare professionals are essential for providing holistic support and optimizing treatment outcomes. Moreover, advancements in therapeutic approaches, including extended half-life clotting factor concentrates, combination antiretroviral therapy, and psychosocial support services, offer promise for improving outcomes and enhancing the quality of life of individuals living with hemophilia and HIV. By leveraging these advancements and adopting a holistic approach to care that addresses the physical, emotional, and social dimensions of living with chronic illness, healthcare providers can empower individuals to navigate the complexities of their conditions and lead fulfilling lives.

References

1. Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. *Blood, The Journal of the American Society of Hematology*. 2019;133(5):415-524.
2. Patton LL. Bleeding and clotting disorders. *Burket's oral medicine: diagnosis and treatment*. 10th ed. Hamilton (ON): BC Decker. 2003:454-477.
3. Livanou ME, Matsas A, Valsami S, Papadimitriou DT, Kontogiannis A, Christopoulos P. Clotting Factor Deficiencies as an Underlying Cause of Abnormal Uterine Bleeding in Women of Reproductive Age: A Literature Review. *Life*. 2023;13(6):1321.
4. Bauer KA. Current challenges in the management of hemophilia. *Am J Manag Care*. 2015;21(6 Suppl):S112-22.
5. Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, Blanchette V. Haemophilia. *Nature reviews Disease primers*. 2021 Jun 24;7(1):45.
6. Karim MA, Jamal CY. A review on hemophilia in children. *Bangladesh J Child Health*. 2013;37(1):27-40.
7. Obeagu EI. Haemophilia B: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2022;9(1):14-20.
8. Okoroiwu IL, Obeagu EI, Egbuobi LN, Ibekwe AM, Vincent CC, Unaeze BC, Adike CN, Chijioke UO, Okafor CJ, Soremi AO, Chukwurah EF. Evaluation of Factor VIII and Factor IX Activity among Primary School Children in Owerri, Imo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021 Jul 3;33(34B):235-41.
9. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):14-7.
10. Obeagu EI, Eze RI, Nwakulite A, Obeagu GU, Babar Q. AN UPDATE ON HAEMOPHILIA A. A. *Journal of Medicine and Health Sciences*. 2021;1(1):7-18.
11. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(8):22-6.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

12. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC Owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-6.
13. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev*. 2015;3:139-44.
14. Obeagu EI, Obeagu GU, Kama SC. Fibrin degradation product and Haemorrhage. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2022;9(1):21-7.
15. Obeagu E, Nwosu D, Obeagu III G. Antithrombin III: A Review. *Int. J. Curr. Res. Biol. Med*. 2022;7(2):20-7.
16. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
17. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
18. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
19. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
20. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
21. McCann SR. *A History of haematology: from Herodotus to HIV*. Oxford University Press; 2016.
22. McCann SR. *A History of haematology: from Herodotus to HIV*. Oxford University Press; 2016.
23. Provan D. *Oxford handbook of clinical haematology*. Oxford University Press, USA; 2009.
24. Doering CB, Archer D, Spencer HT. Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells. *Advanced drug delivery reviews*. 2010;62(12):1204-1212.
25. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
26. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

27. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
29. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
30. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
31. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
32. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf)
33. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
34. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov*. 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
35. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev*. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
36. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res*. 2018;6(1):1-4.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](#)

37. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](#)
38. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
39. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](#).
40. Adeyemo TA, Adeyemo WL, Adediran A, Abd Jaleel AA, Akanmu AS. Orofacial manifestations of hematological disorders: Anemia and hemostatic disorders. *Indian Journal of Dental Research.* 2011;22(3):454-461.
41. Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. In *Seminars in thrombosis and hemostasis* 2008; 01: 128-141.
42. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. *Clinical chemistry.* 2003;49(10):1573-1578.
43. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
44. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022;29-34.
45. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
46. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](#).
47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](#) [links/6516faa61e2386049de5e828/A-Review-of-](#)

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

[knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](#)

48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](#) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](#).
49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](#) https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf
50. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
51. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137](#) [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](#).
52. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
53. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
54. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International.* 2021;33(57A):360-368.
55. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
56. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

- PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
57. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.ejournals.org/links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
 58. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
 59. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ejournals.org/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
 60. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ejournals.org/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
 61. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ejournals.org/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
 62. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910.
https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
 63. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
 64. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
 65. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

66. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research*. 2014; 391:186-189.
67. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
68. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
69. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
70. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
71. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
72. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
73. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
74. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
75. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
76. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
77. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.

78. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
79. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
80. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
81. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
82. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
83. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
84. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024;103(9): e37354.
85. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
86. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
87. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
88. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
89. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijiar.com>;12(01)*.
90. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
91. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijiar.com>;12(01)*.
92. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
93. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
94. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
95. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
96. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

97. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
98. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
99. Gonzalez VD. Innate and adaptive cellular immunity in chronic HCV and HIV-1 infection. Karolinska Institutet (Sweden); 2009.
100. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
101. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
102. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
103. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
104. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
105. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
106. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: <http://www.journalijiar.com>;12(01).
107. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
108. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
109. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
110. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
111. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
112. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

113. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.
114. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.
115. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
116. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
117. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*. 2024;2(2):60-73.
118. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
119. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*. 2024;2(2):33-46.
120. Scott JA, Chew KW. Treatment optimization for HIV/HCV co-infected patients. *Therapeutic advances in infectious disease*. 2017;4(1):18-36.
121. Pooranangadevi N, Padmapriyadarsini C. Treatment of tuberculosis and the drug interactions associated with HIV-TB co-infection treatment. *Frontiers in Tropical Diseases*. 2022; 3:834013.
122. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):11-24.
123. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
124. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology*. 2024;2(3):33-44.
125. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
126. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: <http://www.journalijiar.com>;12(01)*.
127. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijiar.com>;12(01)*.
128. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

129. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
130. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.
131. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
132. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
133. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):41-51.
134. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
135. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*. 2024;2(3):1-8.
136. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
137. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2 (3):42-57.
138. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*. 2024;2(1):1-6.
139. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
140. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
141. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*. 2024;2(2):16-29.
142. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
143. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science*. 2024;2(2):1-7.
144. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
145. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

146. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):42-60.
147. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-5.
148. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology*, 2024; 2 (3):25-41.
149. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
150. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*. 2024;2(2):43-59.
151. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science*. 2024;2(3):23-35.
152. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
153. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):84-99.
154. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*. 2024;2(2):20-35.
155. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine*. 2024;2(2):30-46.
156. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
157. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*. 2024;2(1):35-51.
158. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. *Elite Journal of Medicine*. 2024;2(3):48-59.
159. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*. 2024;2(2):43-59.
160. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):14-32.

Citation: Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27

161. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*. 2024;2(1):17-41.
162. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.
163. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*, 2024; 2 (3):111-117.
164. Obeagu EI, Ngomo SSI. Erythrocyte Morphology in Hemophilia Patients Co-infected with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 72-89
165. Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology*, 2024; 2(5): 90-107